Very long-chain acyl-CoA dehydrogenase (VLCAD) is a mitochondrial enzyme that breaks down long-chain fatty acids (14 to 20 carbons in length) for energy — a process called β-oxidation¹¹ β-oxidation
Mitochondrial β-oxidation is the main pathway for releasing energy from fats. Each cycle shortens a fatty acid chain by two carbons, generating acetyl-CoA and reducing equivalents (NADH, FADH2) that feed the electron transport chain. When VLCAD is impaired, long-chain fats accumulate, cells cannot generate ATP from fat, and toxic intermediates build up in muscle and other tissues.

The p.Val283Ala variant (c.848T>C, NM_000018.4) is the single most common VLCAD deficiency-causing variant identified in the United States. In a large cohort of 693 individuals who tested positive on newborn screening, at least one copy of p.V283A was present in approximately 10% of all affected individuals²² at least one copy of p.V283A was present in approximately 10% of all affected individuals
Miller et al., Mol Genet Metab, 2015. Because the variant permits residual enzyme activity (estimated at 10–25% of normal), it is associated with a milder, late-onset phenotype rather than the severe infantile cardiomyopathy seen with null mutations.

The Mechanism

Valine at position 283 sits within the active-site binding channel of VLCAD, a region critical for anchoring long-chain acyl-CoA substrates during dehydrogenation. The substitution of alanine — a smaller, less hydrophobic amino acid — alters the geometry of the substrate-binding pocket, reducing catalytic efficiency while preserving enough protein folding and assembly for partial function.

This partial loss of function³³ partial loss of function
As opposed to null mutations (frameshifts, nonsense, splice-site) that eliminate VLCAD protein entirely, the V283A substitution maintains a catalytically active enzyme with reduced turnover rate. This residual activity is sufficient to prevent infantile cardiomyopathy but insufficient under metabolic stress explains the phenotypic pattern: under resting, well-fed conditions, alternative energy pathways (glucose oxidation, medium-chain fatty acid metabolism via MCAD) compensate adequately. Under metabolic stress — prolonged exercise, fasting, febrile illness, or anesthesia — the impaired VLCAD pathway becomes the bottleneck, causing energy failure in skeletal muscle (rhabdomyolysis) or liver (hypoglycemia).

The Evidence

Genotype-phenotype correlation: A landmark study by Andresen et al.⁴⁴ Andresen et al.
Andresen et al., Am J Hum Genet, 1999 — 73 patients with VLCAD deficiency genotype-phenotype analysis established that mutations permitting residual enzyme activity consistently associate with the milder myopathic (adult-onset) phenotype, while null mutations (no residual activity) cause severe infantile disease with cardiomyopathy, hypoketotic hypoglycemia, and high mortality. This is a notably clear genotype-phenotype relationship compared to other fatty acid oxidation disorders.

US newborn screening cohort: Miller et al. 2015⁵⁵ Miller et al. 2015
Miller et al., Mol Genet Metab, 2015 — 693 individuals with positive newborn screens, 94 distinct ACADVL variants identified confirmed p.V283A as the most frequent single pathogenic variant, present in roughly 1 in 10 positive screens. Seven patients homozygous for V283A showed a mild phenotype responding well to standard treatment, though hypoglycemic episodes remained a clinical concern.

Long-term outcomes under treatment: A Utah-based longitudinal cohort of 26 VLCAD-deficient patients⁶⁶ 26 VLCAD-deficient patients
Rovelli et al., Mol Genet Metab, 2019 — median follow-up not specified; all ages from newborn to young adult found that treatment-compliant patients normalized biochemical parameters (C14:1-acylcarnitine, creatine kinase) and experienced no major clinical events, including no cardiac involvement beyond infancy. C14:1-carnitine levels — the primary biomarker for VLCAD enzyme function — correlated significantly with creatine kinase levels, making both useful for monitoring muscle involvement.

Practical Actions

For homozygous V283A individuals, management centers on three principles:

1. Avoid prolonged fasting: The impaired long-chain fatty acid pathway becomes critical when glycogen stores deplete (typically after 4–6 hours without carbohydrates in adults, sooner in children). Emergency protocols for illness and surgical procedures must include IV dextrose to bridge periods when oral intake is impossible.

2. Dietary modification: A low long-chain fat / high-MCT diet provides fat-based energy through a route that bypasses VLCAD. Medium-chain fatty acids (8–12 carbons) are processed by MCAD and other shorter-chain dehydrogenases, not VLCAD. MCT oil or triheptanoin (a 7-carbon triglyceride) can substitute for long-chain dietary fats.

3. Exercise management: High-intensity and prolonged aerobic exercise preferentially mobilizes long-chain fatty acids; pre-exercise carbohydrate loading and MCT supplementation reduce reliance on the impaired VLCAD pathway during activity.

Heterozygous carriers (TC genotype) have one functional ACADVL copy and are generally asymptomatic; carrier status is worth documenting for family screening purposes given the recessive inheritance pattern.

Interactions

VLCAD deficiency interacts with other fatty acid oxidation pathway enzymes. Compound heterozygosity — one V283A allele plus a different pathogenic ACADVL allele on the other chromosome — produces variable phenotypes depending on the second allele's functional impact. Individuals compound heterozygous for V283A and a null allele may have intermediate enzyme activity and unpredictable phenotype severity.

The ACADM gene (rs121434280, rs121434281)⁷⁷ ACADM gene (rs121434280, rs121434281)
ACADM encodes medium-chain acyl-CoA dehydrogenase (MCAD), which processes 6–12 carbon fatty acids. MCAD deficiency is the most common fatty acid oxidation disorder. In VLCAD deficiency, the MCT supplement strategy relies on intact MCAD activity — concurrent MCAD deficiency would eliminate this compensatory pathway and the CPT2 gene (rs201065226) — which gates long-chain fatty acid entry into mitochondria upstream of VLCAD — are relevant pathway partners.

VLCAD deficiency also interacts significantly with metabolic state: concurrent hypothyroidism, pregnancy (third trimester), or high-intensity athletic training substantially increases long-chain fatty acid demand and the risk of decompensation events.

PD-1 (Programmed Death-1, encoded by PDCD1) is one of the immune system's most powerful braking mechanisms. Expressed on activated T cells, PD-1 binds its ligands PD-L1 and PD-L2 on antigen-presenting cells and peripheral tissues, suppressing T-cell activation and preventing immune attacks on self-tissue. When this brake is too strong, it enables cancer cells to evade immunity — which is why PD-1 blockade therapies (pembrolizumab, nivolumab) have revolutionised oncology. But when the brake is too weak or dysregulated, autoreactive T cells escape suppression and attack the body's own organs.

The rs11568821 variant, historically named PD1.3¹¹ PD1.3
Named by Prokunina et al. who systematically catalogued PDCD1 polymorphisms in 2002, sits within an intronic enhancer element of the PDCD1 locus at chromosome 2q37.3. It also falls within 2 kb upstream of the long non-coding RNA LOC105373977, which may contribute independent regulatory effects. The G allele at this position is classified as a risk factor for systemic lupus erythematosus (SLE) and as a modifier of multiple sclerosis (MS) disease progression in ClinVar.

The Mechanism

The PD1.3 position falls within an intronic enhancer element in PDCD1's fifth intron²² element in PDCD1's fifth intron
Intronic enhancers are cis-regulatory sequences within gene introns that loop to promoters and control transcription factor recruitment. The G allele disrupts a consensus binding motif for RUNX1³³ RUNX1
RUNX1 (runt-related transcription factor 1) is expressed in immune cells and regulates the expression of numerous immune-function genes including T-cell inhibitory receptors, a transcription factor with broad regulatory roles in haematopoietic and immune cell development. The C allele preserves the RUNX1 binding site; the G allele disrupts it. Because RUNX1 is thought to drive PDCD1 expression through this enhancer, the G allele likely reduces PDCD1 transcription in activated T cells — meaning G allele carriers produce less PD-1 on their T-cell surface, weakening the immune checkpoint and increasing the likelihood that autoreactive T cells escape suppression.

This is the same general class of mechanism as other well-validated autoimmune checkpoint variants: rs3087243 in CTLA4 reduces a different immune brake by destabilising CTLA-4 mRNA, and rs2476601 in PTPN22 impairs an intracellular phosphatase that damps T-cell receptor signalling. All three variants weaken different layers of peripheral T-cell tolerance, and carrying multiple risk variants compounds susceptibility across multiple autoimmune diseases.

The Evidence

The original discovery by Prokunina et al. (2002)⁴⁴ Prokunina et al. (2002)
Nature Genetics — first genome-wide analysis of PDCD1 polymorphisms and SLE susceptibility in Swedish, European-American, and Mexican cohorts found the G allele (reported in that paper as the 'A' allele in minus-strand notation, hence "PD1.3 G/A" in much of the older literature) at approximately 12% in European SLE patients versus 5% in European healthy controls, with a relative risk of 2.6 in Europeans and 3.5 in Mexicans. This was a landmark paper establishing that a non-coding intronic variant in a negative immune regulator could confer meaningful autoimmune susceptibility.

Population-specific effects⁵⁵ Population-specific effects
Different populations show variable LD between PD1.3 and other PDCD1 variants, which may explain why the same G allele appears protective in some cohorts are a notable feature of this locus. A large Spanish cohort study (518 SLE patients, 800 controls) found the opposite association: the G allele was less frequent in Spanish female SLE patients (OR 0.67). The authors attributed this to different haplotype backgrounds in the Spanish versus Northern European and Mexican populations — the risk conferred by PD1.3 appears to depend on which other PDCD1 variants it travels with.

For multiple sclerosis, ClinVar records the G allele as a modifier of disease progression (RCV000009833), and a 2023 case-control study of 229 MS patients⁶⁶ 2023 case-control study of 229 MS patients
Hassani et al., Immunol Med, 229 MS patients and 246 controls found trends consistent with a modest risk contribution, though the effect did not reach conventional significance thresholds in that sample.

An Egyptian female cohort (70 SLE patients, 80 controls) found GG homozygotes enriched among SLE patients (67.1% in patients vs controls, p=0.023)⁷⁷ SLE patients (67.1% in patients vs controls, p=0.023)
Abo El-Khair et al. 2019, Lupus — the G allele frequency was 82.1% in SLE cases, p=0.0021, with strong linkage disequilibrium between PD1.3 and a second PDCD1 variant. This study's finding that the major GG genotype was risk-enriched illustrates how population-stratified haplotypes complicate interpretation at this locus.

It is important to note that multiple studies — including a Southern Brazilian cohort of 95 SLE patients and 87 RA patients — found no significant association⁸⁸ no significant association
PD1.3 A allele frequencies 0.095 in SLE, 0.115 in RA, 0.078 in controls — differences not statistically significant. The overall evidence for rs11568821 is moderate: biologically plausible, replicated in some populations, but inconsistent across cohorts and ancestry groups.

Practical Implications

Carrying the G allele at rs11568821 is not a diagnosis or a certainty of autoimmune disease. The risk increase is moderate (relative risk approximately 1.5–2.6 in populations where the association holds), and the G allele is rare enough (approximately 2–5% in most European populations) that most carriers never develop SLE or MS.

The clinical value of this variant lies in cumulative risk profiling: if you also carry risk variants in CTLA4 (rs3087243 GG), PTPN22 (rs2476601 AT), or STAT4 (rs7574865 TT), the combined signal is more informative than any single variant. Women carry substantially higher lifetime risk for SLE (9:1 female predominance), so the G allele is most clinically relevant for women with a personal or family history of autoimmune disease.

For PD-1 checkpoint immunotherapy: some evidence suggests that germline variation in PDCD1 may influence the balance between immunotherapy efficacy and autoimmune side effects, though this pharmacogenomic connection is not yet established at the clinical level.

Interactions

The PD1.3 variant operates within a broader PDCD1 haplotype context. rs2227981 (PD1.5 C/T)⁹⁹ rs2227981 (PD1.5 C/T)
A second PDCD1 variant in an exonic position that has been studied alongside PD1.3 in haplotype analyses and rs36084323 (PD1.1 G/A) are studied alongside rs11568821 in haplotype analyses; the GACT haplotype (combining all four common PDCD1 variants) showed the strongest SLE association in an Iranian cohort (OR 9.76, p<0.001). These variants are in linkage disequilibrium with each other and the risk they collectively confer is greater than any single variant.

The broader autoimmune checkpoint landscape includes CTLA4 rs3087243 (T-cell co-stimulatory brake) and PTPN22 rs2476601 (T-cell receptor signalling phosphatase) — both expressed in the same T-cell tolerance pathway. Carriers of G alleles at rs11568821 alongside risk alleles at these other immune checkpoint genes face compounding susceptibility to multiple autoimmune conditions, especially SLE and RA.

rs11591147 encodes the R46L (p.Arg46Leu) variant in PCSK9, a serine protease that regulates LDL cholesterol by promoting degradation of LDL receptors in the liver.

This loss-of-function mutation is associated with 15-47% reductions in coronary heart disease risk , making it one of the most significant cardioprotective genetic variants discovered. The variant provided the biological proof-of-concept for PCSK9 inhibitor drugs¹¹ PCSK9 inhibitor drugs
monoclonal antibody medications like evolocumab and alirocumab that mimic the effects of this variant.

The Mechanism

The R46L variant is a missense mutation in exon 1 of PCSK9 that replaces arginine with leucine at position 46 . This amino acid substitution in the prodomain²² prodomain
the N-terminal region cleaved during PCSK9 maturation reduces PCSK9 protein secretion efficiency and plasma PCSK9 concentration . The result: more LDL receptors remain on liver cell surfaces, pulling more cholesterol out of circulation.

The variant reduces protein secretion, phosphorylation, and binding affinity for the LDL receptor , creating a lifelong reduction in LDL cholesterol from birth onward.

The Evidence

The R46L variant was first identified in Cohen et al.'s landmark 2006 NEJM study³³ Cohen et al.'s landmark 2006 NEJM study
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease of the Atherosclerosis Risk in Communities (ARIC) cohort.

Among 9,524 white subjects, 3.2% carried R46L and had 15% lower LDL cholesterol and a 47% reduction in coronary heart disease over 15 years of follow-up. The effect was dose-dependent: heterozygotes averaged 116 mg/dL LDL while the eight homozygotes averaged 112 mg/dL .

A 2010 meta-analysis⁴⁴ A 2010 meta-analysis
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease of three Danish cohorts totaling 66,698 subjects confirmed the effect.

R46L carriers had a 12% (0.43 mmol/L) reduction in LDL-C and a 28% reduction in risk of ischemic heart disease . Remarkably, the observed 28% risk reduction far exceeded the 5% reduction predicted by the LDL lowering alone , suggesting that lifelong exposure to lower LDL — not just magnitude of reduction — drives the benefit.

The CARDIA longitudinal study⁵⁵ CARDIA longitudinal study
tracking the same individuals from age 18 to 50 demonstrated this lifelong effect.

R46L carriers had significantly lower LDL at age 18 (84.4 vs 100.9 mg/dL) and maintained this advantage through middle age .

This long-term LDL reduction was associated with reduced carotid intima-media thickness and lower coronary calcification in middle age .

Even in familial hypercholesterolemia (FH) — a genetic disorder causing severe high cholesterol — the R46L variant exerts a protective effect.

In a cohort of 582 FH patients, the 3% carrying R46L had 11% lower LDL cholesterol and significantly lower cardiovascular disease risk compared to non-carriers . The variant doesn't cure FH, but it substantially attenuates the phenotype.

Beyond cardiovascular protection,

R46L carriers are protected against nonalcoholic fatty liver disease (NAFLD), NASH, and liver fibrosis , with an odds ratio of 0.42 for NAFLD in a study of 1,874 at-risk individuals.

Carriers also have lower carotid intima-media thickness and, in males, reduced erectile dysfunction prevalence

— both markers of systemic vascular health.

Practical Implications

If you carry one or two copies of the R46L variant (GT or TT genotypes), you have a naturally lower LDL cholesterol baseline and substantially reduced lifetime cardiovascular risk. This is not a reason to ignore cardiovascular health, but it does mean your starting point is more favorable than average. Your LDL may appear "borderline" when it's actually protective for you.

The R46L variant does not eliminate the need for lifestyle interventions — diet, exercise, not smoking — but it provides a genetic cushion. If you develop high LDL despite carrying R46L, investigate secondary causes: hypothyroidism, familial hypercholesterolemia from other genes (LDLR, APOB), or metabolic syndrome. In the rare event you need statin therapy, you may respond more favorably and require lower doses than predicted.

If you don't carry R46L (GG genotype), the existence of PCSK9 inhibitor drugs means pharmaceutical options can mimic the protective effects of this variant. These drugs — evolocumab, alirocumab, inclisiran — lower LDL by 50-60% and reduce cardiovascular events in high-risk populations. The biology discovered through R46L carriers has translated directly into therapy.

Interactions

PCSK9 R46L interacts with other lipid metabolism genes but does not require compound implication entries because its effect is independent and additive. Carriers of R46L who also have:

• APOE ε4 alleles (rs429358, rs7412) — the cardiovascular risk from APOE4 is partially offset by R46L's LDL-lowering effect, but APOE4 still increases Alzheimer's risk independent of cholesterol.
• LDLR or APOB mutations (familial hypercholesterolemia) — as demonstrated in the FH cohort studies, R46L attenuates but does not eliminate the severe LDL elevation. These individuals still require aggressive lipid management but start from a lower baseline.
• Statin metabolism variants (SLCO1B1 rs4149056, CYP3A4/5 variants) — R46L does not change statin pharmacokinetics, but carriers may achieve target LDL levels with lower statin doses due to their baseline advantage.

Other PCSK9 variants include gain-of-function mutations (E670G, D374Y, S127R) that increase LDL and cardiovascular risk, and additional loss-of-function mutations (Y142X, C679X — predominantly in African populations) that confer even stronger protection than R46L. These are distinct variants, not alleles of the same SNP, so there is no compound heterozygosity with R46L at this locus.

The kidneys are the primary route of uric acid excretion, and their efficiency depends on a balance between transporters that reabsorb urate from the filtrate and those that secrete it into urine for elimination. On the apical (urine-facing) surface of the proximal tubule, NPT1 (sodium-dependent phosphate transport protein 1), encoded by SLC17A1, acts as a urate efflux transporter — pumping uric acid from tubular cells into the tubular lumen¹¹ NPT1 (sodium-dependent phosphate transport protein 1), encoded by SLC17A1, acts as a urate efflux transporter — pumping uric acid from tubular cells into the tubular lumen. rs1165196 is a missense variant in SLC17A1 that directly changes the protein's amino acid at position 269 (Thr↔Ile), and this change has measurable consequences for how efficiently NPT1 exports urate from the kidney.

The Mechanism

The A allele at rs1165196 encodes isoleucine at position 269 (Ile269) — the common form of NPT1 in most global populations. The G allele encodes threonine at the same position (Thr269), and this substitution alters the transport kinetics of the protein. Functional studies using Xenopus oocyte expression systems showed that the Thr269 variant increases urate transport by raising the maximum transport rate (Vmax) without changing the substrate affinity (Km) or membrane expression level²² the Thr269 variant increases urate transport by raising the maximum transport rate (Vmax) without changing the substrate affinity (Km) or membrane expression level
Sakiyama et al. 2016: gain-of-function mechanism confirmed in NPT1 I269T (Thr269) variant. This means the Thr269 protein is intrinsically more active — each transporter molecule moves more urate per unit time — without the cell needing to produce more copies.

The net effect is a higher urate secretory rate in the proximal tubule, directly lowering the serum urate setpoint in Thr269 carriers. Carriers of the Ile269 form (A allele) have baseline NPT1 activity and correspondingly higher serum urate relative to Thr269 carriers.

The Evidence

The functional significance of rs1165196 was established in a study of 582 Japanese gout patients and controls: the Thr269 variant significantly decreased risk of renal underexcretion gout (OR 0.73, p=0.031), confirming that enhanced NPT1 urate export reduces the most common gout subtype³³ the Thr269 variant significantly decreased risk of renal underexcretion gout (OR 0.73, p=0.031), confirming that enhanced NPT1 urate export reduces the most common gout subtype
Chiba et al. 2015, Arthritis & Rheumatology. Renal underexcretion gout accounts for approximately 80–90% of primary gout cases, making NPT1 function a clinically important determinant. An earlier study of 103 Japanese male gout patients found the coding-equivalent C allele (Thr269) protective against gout at OR 0.55 (p=0.0035)⁴⁴ the coding-equivalent C allele (Thr269) protective against gout at OR 0.55 (p=0.0035)
Urano et al. 2010, Annals of the Rheumatic Diseases, with a significant gene-obesity interaction: the protective effect on serum uric acid was amplified in individuals with BMI ≥25.

The rs1165196 locus overlaps with the broader SLC17A1 GWAS signal for serum urate. The linked intronic variant rs1183201 reached genome-wide significance (p=3.0×10⁻¹⁴) in a meta-analysis of 28,141 Europeans, confirming that this chromosomal region materially influences the renal urate setpoint across populations.

The Thr269 allele (G on the plus strand) reaches its highest frequency in Europeans (~44%) and South Asians (~47%), while the Ile269 allele (A) is dominant in East Asian (~85%) and African (~89%) populations. This ancestry stratification helps explain why gout prevalence differs substantially across populations and is particularly relevant for interpreting genetic risk in multi-ancestry settings.

Practical Actions

For carriers of the AA genotype (Ile/Ile), NPT1 operates at baseline efficiency. Since approximately 80–90% of gout is driven by renal underexcretion rather than overproduction, reduced secretory capacity from this locus compounds with other urate transport variants to elevate the serum urate setpoint. Dietary purine management (limiting shellfish, organ meats, and fructose-sweetened beverages) reduces the substrate load the kidney must clear.

For AG heterozygotes, one NPT1 allele carries the gain-of-function Thr269 and the other the baseline Ile269, yielding intermediate urate secretory capacity. Periodic monitoring of serum uric acid is warranted, especially if other urate-raising variants are present.

Interactions

rs1165196 is in linkage disequilibrium (r² ≈ 0.8–0.9) with the intronic variant rs1183201 in the same gene, which has more direct GWAS association data for serum urate. Both variants capture the same biological signal — NPT1-mediated urate secretory capacity at the SLC17A1 locus. When both are genotyped, rs1165196 provides the mechanistic interpretation (gain-of-function protein change) while rs1183201 provides population-level effect size data.

The most clinically important interaction is with rs2231142 in ABCG2, the second major apical urate secretory transporter. ABCG2 Q141K (rs2231142 T allele) reduces ABCG2 transport activity by approximately 50%, and carriers of both SLC17A1 Ile269 (A allele) and ABCG2 Q141K have dual impairment of apical urate secretion — both major secretory routes compressed simultaneously. This compound effect is especially prevalent in East Asian populations and substantially elevates gout risk beyond either variant alone.

Angiopoietin-like protein 4 (ANGPTL4¹¹ ANGPTL4
a secreted protein that normally shuts off lipoprotein lipase, the enzyme responsible for clearing triglycerides from the bloodstream) acts as a brake on fat clearance. The E40K variant at rs116843064 partially disables this brake. Carriers of the K40 allele (the minor A allele) have less ANGPTL4-mediated LPL inhibition, leading to faster triglyceride clearance after meals and persistently lower fasting triglyceride levels throughout life. This is one of a small number of naturally occurring human variants in the ANGPTL family with a clearly protective cardiovascular phenotype.

The Mechanism

ANGPTL4 is secreted from the liver and adipose tissue and inhibits lipoprotein lipase (LPL)²² lipoprotein lipase (LPL)
the enzyme anchored to capillary walls that hydrolyzes triglycerides in VLDL and chylomicrons, releasing fatty acids for tissue uptake by promoting its dissociation from the capillary wall. The E40K substitution (p.Glu40Lys) alters the N-terminal coiled-coil domain of ANGPTL4, reducing its inhibitory potency against LPL. With less ANGPTL4-mediated inhibition, LPL remains more active — it clears more triglyceride-rich lipoproteins from circulation, leaving lower fasting and postprandial TG levels. This variant is classified as a partial loss-of-function: it reduces, but does not abolish, ANGPTL4 activity, distinguishing it from complete LOF mutations.

The Evidence

The most definitive evidence comes from two large-scale genetic studies. The 2016 NEJM paper from the MI Genetics and CARDIoGRAM Exome Consortia³³ 2016 NEJM paper from the MI Genetics and CARDIoGRAM Exome Consortia
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. NEJM, 2016 analyzed 72,868 CAD cases and 120,770 controls and found the E40K variant specifically associated with a 14% reduced odds of coronary artery disease (OR 0.86, P=4.0×10⁻⁸). Complete LOF mutations in ANGPTL4 in the same study produced even larger effects (OR 0.47 for MI, and 35% lower triglyceride levels in carriers).

A 2024 phenome-wide analysis by Gagnon et al.⁴⁴ Gagnon et al.
Gagnon E et al. Impact of loss-of-function in angiopoietin-like 4 on the human phenome. Atherosclerosis, 2024 used FinnGen (309,154 participants) and UK Biobank whole-exome data (488,278 participants) to confirm the E40K signal: OR 0.84 for CAD (P=3.6×10⁻²¹) and OR 0.91 for type 2 diabetes (P=2.8×10⁻⁵). Critically, a phenome-wide scan of 1,589 diseases found no significant risk increases attributable to E40K — the variant does not appear to trade cardiovascular benefit for harm elsewhere.

Triglyceride reductions are well-quantified across multiple cohorts. Talmud et al.⁵⁵ Talmud et al.
Talmud PJ et al. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol, 2008 pooled 5 cohorts (n=13,527) and found K40 carriers had 20.4% lower fasting triglycerides (P<0.0001). In the Look AHEAD trial of 2,601 adults with type 2 diabetes, Smart-Halajko et al.⁶⁶ Smart-Halajko et al.
Smart-Halajko MC et al. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial. BMC Med Genet, 2011 found K40 carriers had 0.33 mmol/L (~17%) lower TG than E40 homozygotes (P=0.001). Higher HDL-cholesterol in K40 carriers has also been reported, consistent with the reciprocal relationship between TG clearance and HDL-C levels.

The evidence is rated strong: consistent replication across large independent cohorts, a clear molecular mechanism via LPL de-inhibition, genome-wide significant association with hard cardiovascular outcomes, and phenome-wide safety data. It falls short of established because ANGPTL4 genotyping is not yet incorporated into clinical lipid management guidelines.

Practical Actions

For the rare individual carrying one or two A alleles, the E40K variant provides a durable biological advantage in TG metabolism. Dietary fat composition still matters: while overall TG clearance is enhanced, the variant does not override the acute postprandial TG spike from very high saturated fat loads. Omega-3 fatty acid supplementation (EPA/DHA) works through a partially overlapping pathway — both E40K and high-dose omega-3s reduce VLDL-TG — so carriers may derive additive benefit from omega-3 intake if baseline TG is in the borderline range.

Because triglyceride levels influence remnant lipoprotein particle burden and are an independent cardiovascular risk factor, the 17–20% TG reduction from E40K is clinically meaningful and worth monitoring through standard lipid panels to confirm phenotypic expression.

Interactions

ANGPTL4 E40K operates in the same triglyceride-clearance pathway as APOA5 (rs3135506), which also modulates LPL activity. A carrier of both E40K and the APOA5 S19W variant (which raises TG) might see partially opposing effects — the combined phenotype would depend on effect magnitudes at each locus. Similarly, the APOC3 promoter variants (rs2854116) that elevate ApoC-III and inhibit LPL are in the same downstream pathway: carrying ANGPTL4 E40K alongside an APOC3 TG-raising variant would likely attenuate but not fully overcome the APOC3 effect. No formal published compound analysis exists for these specific genotype combinations, so these remain pathway-level interactions rather than quantified compound effects.

The companion ANGPTL4 variant T266M (rs1044250) has an independent but weaker TG-lowering effect (~10% reduction) and operates through a different structural domain of the protein. Carriers of both E40K and T266M may have additive TG lowering, though compound heterozygosity at these two positions is rare.

Every cell in your body needs zinc, yet humans have no meaningful way to store it. Every milligram must be absorbed fresh from the diet, almost entirely through the duodenum and proximal jejunum. The protein responsible for ferrying zinc from the gut lumen into intestinal cells is ZIP4¹¹ ZIP4
Zinc/Iron Regulated Transporter-related Protein 4 — encoded by SLC39A4 (solute carrier family 39 member 4) on chromosome 8q24.3, a twelve-pass transmembrane transporter that acts as the body's primary zinc gate. When ZIP4 is broken, zinc cannot cross the intestinal wall in sufficient quantities, and the consequences unfold quickly.

The c.599C>T variant (rs121434287) swaps a proline for a leucine at position 200 of the ZIP4 protein (p.Pro200Leu). It is one of the founding mutations identified in acrodermatitis enteropathica²² acrodermatitis enteropathica
AE — from Greek: acral (affecting the extremities and face), dermatitis (skin inflammation), and enteropathica (intestinal disease). First described by Brandt in 1936 and named by Danbolt and Closs in 1943 (AE), a rare autosomal recessive disorder of inherited zinc deficiency. Two copies of pathogenic SLC39A4 variants — either homozygous or compound heterozygous — lead to near-complete failure of intestinal zinc absorption, producing the clinical triad of periorificial and acral dermatitis, chronic diarrhea, and alopecia.

The Mechanism

ZIP4 is an unusual transporter: it moves zinc by coupling zinc influx to proton influx, exploiting the pH gradient at the gut lumen surface. The protein folds into an extracellular domain (ECD) containing two subdomains — the HRD domain and the PCD domain³³ PCD domain
Potentially Conserved Domain — a structural region conserved across ZIP family members — linked by a short linker region that includes Pro200.

Structural studies⁴⁴ Structural studies
Kuliyev E et al. Zinc transporter mutations linked to acrodermatitis enteropathica disrupt function and cause mistrafficking. J Biol Chem, 2021 showed that Pro200 sits in this linker region and that the P200L substitution causes ZIP4 to misfold. The mutant protein fails to traffic to the apical cell surface of enterocytes, becoming trapped in the endoplasmic reticulum with immature glycosylation. The functional result is complete abolition of zinc transport activity — not just a partial reduction. Cells expressing P200L ZIP4 take up zinc at rates indistinguishable from cells expressing no ZIP4 at all.

Functional studies⁵⁵ Functional studies
Hoch E et al. Elucidating the H+ Coupled Zn2+ Transport Mechanism of ZIP4; Implications in Acrodermatitis Enteropathica. Int J Mol Sci, 2020 confirmed that P200L disrupts the proton-coupled zinc transport mechanism specifically, with the mutant showing severely reduced capacity to couple H+ influx to Zn2+ uptake compared to wild-type ZIP4.

The Evidence

Acrodermatitis enteropathica is one of the better-characterized single-gene zinc disorders precisely because its cause was confirmed at the molecular level. SLC39A4 was identified as the AE gene in 2002, and the Pro200Leu variant is among the earliest mutations reported. A comprehensive mutation update⁶⁶ comprehensive mutation update
Schmitt S et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat, 2009 catalogued 44 distinct pathogenic variants, documenting the mutational spectrum across all exons and confirming that most patients carry compound heterozygous mutations rather than two copies of the same variant.

ClinVar lists this variant (VCV000003537) as Pathogenic/Likely pathogenic with criteria provided by seven independent diagnostic laboratories, with no classification conflicts. The associated condition is hereditary acrodermatitis enteropathica (OMIM 201100).

Without zinc replacement, AE follows a predictable course: infants present within weeks of weaning with periorificial dermatitis, diarrhea, failure to thrive, and alopecia. The condition can be fatal if unrecognized. With consistent zinc supplementation (5–10 mg/kg/day elemental zinc for acute disease; 1–2 mg/kg/day for maintenance), symptoms resolve rapidly and prognosis is excellent — lifelong supplementation is required, but patients can live normally.

Heterozygous Carriers

Heterozygous carriers have one functional ZIP4 allele and one P200L allele. With 50% of ZIP4 protein functioning normally, zinc absorption is maintained at sufficient levels for health under normal dietary conditions. Published case series confirm that parents of AE patients — who are obligate heterozygotes — do not develop AE. Some studies have noted that carriers may have modestly reduced zinc absorption under high-demand conditions (illness, pregnancy, poor diet), but this has not been quantified precisely and clinical AE does not occur in heterozygotes.

Practical Actions

Because AE is autosomal recessive, the practical significance of a single heterozygous P200L allele is primarily in the context of family planning and reproductive genetics. Carriers should be aware that if both parents carry a pathogenic SLC39A4 variant, each child has a 25% chance of inheriting biallelic variants and developing AE. Prenatal or preconception genetic counseling is appropriate when a carrier couple is identified.

For homozygous or compound heterozygous individuals, the clinical course depends on early identification and zinc supplementation initiation. Modern diagnostic genetic testing can confirm the diagnosis, and treatment (zinc sulfate orally) is inexpensive, highly effective, and well tolerated.

Interactions

Compound heterozygosity is the rule rather than the exception in AE. Most patients carry two different pathogenic SLC39A4 variants on their two chromosomes — for example, P200L on one chromosome and a frameshift or splice-site mutation on the other. The clinical severity is generally comparable across different compound heterozygous combinations, though some genotype-phenotype variability exists. For AE patients, the supervising clinician should characterize both SLC39A4 alleles to confirm the diagnosis and facilitate family cascade testing.

Antithrombin III — encoded by SERPINC1 — is the body's primary brake on the coagulation cascade. It neutralizes thrombin and activated Factor Xa, directly blocking the two central enzymes that form fibrin clot. When antithrombin works at full capacity, a runaway clotting reaction cannot occur. The Arg79Cys variant destroys part of that brake. Carriers produce antithrombin protein with a crippled heparin-binding domain, and the crippled protein cannot do its job — the coagulation system runs hotter and clots more readily. The result is one of the strongest known inherited thrombophilias, with a risk of venous thromboembolism (VTE) estimated at 14-fold above the general population¹¹ estimated at 14-fold above the general population
Croles et al., 2018 Bayesian meta-analysis of 19 studies, Semin Thromb Hemost.

The Mechanism

The SERPINC1 gene is on the minus strand of chromosome 1 (position 173,914,726 on GRCh38). The Arg79Cys variant arises from a CpG dinucleotide hotspot²² CpG dinucleotide hotspot
CpG sites are hypermutable because cytosine methylation spontaneously deaminates to thymine; recurrent independent mutations at the same codon are common in antithrombin deficiency in exon 2 of SERPINC1, where a G-to-A change on the plus strand converts arginine at position 79 to cysteine in the mature protein. Arginine-79 is located in the [heparin-binding domain | The N-terminal region of antithrombin that physically contacts heparan sulfate proteoglycans on endothelial cells, dramatically accelerating the inhibitory rate constant] near the N-terminus of the protein. Arginine's positively charged guanidinium group makes electrostatic contact with negatively charged heparin; cysteine, with its uncharged thiol, cannot replicate this interaction. The result is a [Type II heparin-binding site (HBS) deficiency | The WHO classifies antithrombin deficiency into Type I (quantitative: low antigen and activity) and Type II (qualitative: normal antigen, reduced activity). Arg79Cys is a Type II HBS variant]: the protein is present in normal amounts but cannot bind heparin at full affinity, impairing the 1,000-fold rate acceleration that heparin normally provides to the inhibitory reaction.

Heterozygous carriers have functional antithrombin activity typically around 50-75% of normal — enough to prevent spontaneous thrombosis in many circumstances, but not enough to withstand strong provoking stimuli: surgery, pregnancy, immobility, estrogen exposure, or concurrent thrombophilic variants.

The Evidence

The evidence base for antithrombin deficiency and VTE is among the most robust in inherited thrombophilia. A Bayesian meta-analysis of 19 studies by Croles and colleagues³³ Bayesian meta-analysis of 19 studies by Croles and colleagues
2018, Seminars in Thrombosis and Hemostasis calculated a pooled OR of 14.0 (95% credible interval 5.5-29.0) for first VTE in antithrombin-deficient individuals. Annual VTE incidence was 1.2% in deficient individuals versus 0.07% in the general population — a 17-fold difference in absolute rates. After a first VTE, annual recurrence without anticoagulation reached 8.8% versus 4.3% in non-deficient patients.

A separate meta-analysis by Di Minno et al.⁴⁴ meta-analysis by Di Minno et al.
13 studies, 3,452 VTE cases; Thrombosis Research 2015 confirmed an OR of 16.26 (95% CI 9.90-26.70), making antithrombin deficiency substantially stronger than either Factor V Leiden (OR ~5-7) or prothrombin G20210A (OR ~3-5).

A nuance relevant to rs121909547 specifically: because Arg79Cys is a Type II HBS mutation, it may carry somewhat lower risk than Type I (quantitative) deficiency. A retrospective cohort of 540 SERPINC1 mutation carriers by Alhenc-Gelas et al.⁵⁵ retrospective cohort of 540 SERPINC1 mutation carriers by Alhenc-Gelas et al.
Thrombosis and Haemostasis 2017 found that Type II HBS mutations had an adjusted relative risk of 0.28 compared to Type I mutations — still representing a substantial absolute VTE risk, but a meaningful gradient worth knowing for clinical counseling. Even at the lower end of the antithrombin deficiency risk spectrum, the absolute VTE risk substantially exceeds that of Factor V Leiden or prothrombin G20210A.

Practical Actions

The clinical management of antithrombin deficiency centers on three domains. First, thromboprophylaxis during high-risk periods: surgery, hospitalization, prolonged immobility, and pregnancy each require active management. Second, contraception and hormonal therapy: estrogen-containing hormonal contraceptives are generally avoided because estrogen is itself prothrombotic and the combination multiplies risk dramatically. Third, anticoagulation after any VTE event: given the high recurrence rate (8.8%/year without anticoagulation), extended or indefinite anticoagulation is typically recommended after a first unprovoked VTE.

Antithrombin concentrate (plasma-derived or recombinant) is available for acute thrombosis or high-risk situations (peri-surgical, peri-partum) in deficient individuals when standard anticoagulation is insufficient. This is a specialist-level intervention, but carriers should know it exists.

Hematology referral for formal thrombophilia evaluation is recommended for all carriers.

Interactions

The most clinically important interactions are additive with other prothrombotic states. A carrier of rs121909547 who also carries Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963) has independent defects in both coagulation inhibition and coagulation factor overproduction — a multiplicative risk combination. Acquired prothrombotic conditions (antiphospholipid syndrome, myeloproliferative neoplasms, cancer, nephrotic syndrome) also compound with antithrombin deficiency in a clinically significant way.

During pregnancy, antithrombin levels physiologically decline by 20-30% in the third trimester, which means a carrier starts closer to the critical threshold for thrombosis and falls below it more easily. Antithrombin concentrate is sometimes used peripartum in this setting.

Of all the proteins that build your teeth, enamelin is the largest and arguably the most architecturally critical. Secreted by ameloblasts — the cells that construct enamel — enamelin functions at the mineralization front¹¹ enamelin functions at the mineralization front
the leading edge where enamel mineral ribbons initiate and elongate along the outer surface of the ameloblast membrane, guiding hydroxyapatite crystals into their organized, interlocking arrangement. Without sufficient functional enamelin, the mineralization front fails: crystals do not form properly, and the resulting enamel is thinner, softer, and structurally compromised from the day teeth erupt.

The rs12640848 variant sits in intron 8 of the ENAM gene on chromosome 4q13.3. It does not change the enamelin protein sequence, but intronic variants at this location can alter splice enhancer activity, mRNA splicing efficiency, or transcript expression levels during the brief, irreversible window when enamel is being built. Multiple studies across European, South Asian, and Latin American populations have examined how this variant influences dental caries susceptibility, with the reference A allele consistently associated with higher caries risk and the alternate G allele appearing protective in studies where a significant effect is observed.

The Mechanism

Enamelin is secreted during the secretory stage of amelogenesis alongside amelogenin and ameloblastin. It binds tightly to the forming enamel crystallites and is thought to regulate their elongation and lateral growth — essentially controlling the architecture of enamel from the inside out. Pathogenic ENAM mutations cause autosomal-dominant amelogenesis imperfecta²² autosomal-dominant amelogenesis imperfecta
a condition where enamel is absent, severely thin, or structurally disorganized; even one mutated copy of ENAM can produce pitted, grooved, or hypoplastic teeth in severe cases, confirming that the gene operates in a dose-sensitive manner during tooth development.

The intronic location of rs12640848 means the variant likely exerts a quantitative rather than qualitative effect — subtly modulating how much functional enamelin is produced or how efficiently the transcript is processed during enamel formation. Individuals carrying one or two A alleles may produce marginally less effective enamelin, resulting in enamel that is structurally adequate but more vulnerable to acid-mediated demineralization and caries initiation over time.

The Evidence

The most detailed study of rs12640848 examined 96 Polish preschool children (48 with caries, 48 caries-free) using a case-control design. Gerreth et al. (2016) found the G allele significantly more prevalent in the caries-free group³³ Gerreth et al. (2016) found the G allele significantly more prevalent in the caries-free group
Clinical Oral Investigations 2016; n=96 children aged 20–42 months; G allele: 65% in controls vs. 45% in cases; p=0.0062. The GG homozygous genotype was dramatically protective: 38% of caries-free children had GG versus only 6% of caries-affected children (OR 9.0, p=0.0010). Heterozygous AG children showed intermediate risk compared to GG controls. Importantly, a neural network model trained on 95 Polish children⁴⁴ neural network model trained on 95 Polish children
Zaorska et al., Genes 2021; combined SNP panel achieved 90% sensitivity and 96% specificity (AUC 0.970) for caries prediction identified rs12640848 as one of the strongest genetic predictors in the panel (p=0.0401 in the final logistic regression model).

A South Indian study of 361 children and young adults replicated the protective G allele signal: the heterozygous AG genotype was associated with dental caries at OR 3.041 (p=0.006), and the G allele itself showed a significant protective association (OR 1.478, p=0.02) — consistent with the direction seen in Polish children.

In contrast, a Czech case-control study of 905 children found no significant association between rs12640848 and caries in either primary or permanent dentition. Borilova Linhartova et al. (2018) concluded that ENAM rs12640848 cannot be used as a risk factor in the Czech population⁵⁵ Borilova Linhartova et al. (2018) concluded that ENAM rs12640848 cannot be used as a risk factor in the Czech population
Clinical Oral Investigations 2018; n=905 children; primary dentition: 78 caries-free, 109 ECC cases; permanent: 177 caries-free, 541 with caries; no significant genotype or allele difference in either cohort. A meta-analysis pooling seven studies (1,256 cases, 710 controls) found no significant overall association (OR=1.15, 95% CI: 0.88–1.52, p=0.310), with considerable heterogeneity across populations.

A Mexican study of 71 children under high vs. low fluoride exposure found that GG genotype frequency was significantly higher in children with severe dental fluorosis⁶⁶ GG genotype frequency was significantly higher in children with severe dental fluorosis
Duran-Merino et al., Int J Environ Res Public Health 2020; GG: 22% in TF≥5 fluorosis group vs. 8.3% controls; p=0.000, suggesting that the G allele interacts with high fluoride exposure in a way that may not be straightforwardly protective under all environmental conditions.

The overall picture: rs12640848 has a genuine biological foothold in enamel vulnerability, with plausible population-specific modulation by dietary, fluoride, and microbial environment. The evidence is best characterized as moderate — consistent in direction in the populations where it reaches significance, but not yet showing a pooled effect across all populations.

Practical Actions

Because enamel is laid down before teeth erupt and cannot be rebuilt from within, the focus for AA carriers is to protect existing enamel from acid challenge and support remineralization on its surface. Topical fluoride is the most directly evidence-matched intervention: it promotes remineralization of enamel and has a known mechanistic connection to enamel matrix gene expression. Limiting the frequency of acid exposure — not just amount — preserves the neutral-pH windows during which enamel naturally remineralizes between acid challenges. Supplementing with remineralizing agents (nano-hydroxyapatite, CPP-ACP) provides mineral delivery complementary to fluoride.

Interactions

rs12640848 has been studied alongside other ENAM variants (rs7671281, rs3796704) and the AMELX variant rs17878486. Gene cluster analyses of enamel-formation SNPs consistently show stronger combined signals than individual variants, supporting a polygenic model of enamel susceptibility where ENAM, AMELX, KLK4, and MMP20 variants collectively determine enamel quality. If you carry risk variants at multiple loci in this enamel-formation cluster, the combined susceptibility is greater than any single variant suggests. The KLK4 rs2242670 and ENAM rs12640848 variants represent sequential phases of enamel development — structural matrix secretion (ENAM) and matrix protein clearance (KLK4) — and carriers of risk alleles at both loci may benefit from a more intensive preventive protocol than either alone would suggest.

The BRCA1 gene is one of the most well-known genes in human genetics, encoding a large protein essential for homologous recombination DNA repair¹¹ homologous recombination DNA repair
A high-fidelity mechanism for repairing double-strand DNA breaks using the sister chromatid as a template; BRCA1 orchestrates the assembly of the repair complex. Pathogenic mutations in BRCA1 dramatically increase lifetime risks of breast (60-70%) and ovarian (40-50%) cancer. However, not every variant in BRCA1 is pathogenic. The E1038G variant (rs16941) is a common missense polymorphism carried by roughly one-third of the global population — fundamentally different from the rare, high-penetrance BRCA1 mutations that drive clinical management decisions like prophylactic surgery.

This distinction is critical. If you carry this variant, it does not mean you have a "BRCA1 mutation" in the clinical sense. The E1038G variant has been classified as likely benign to benign by most ClinVar submitters, though a small number of association studies have reported modest risk elevations (OR ~1.1-1.3) for breast cancer. Current evidence places it in the category of a common variant with uncertain-to-modest biological significance — potentially a minor risk modifier, but not an actionable pathogenic finding.

The Mechanism

The rs16941 variant causes a glutamic acid-to-glycine substitution at position 1038 of the BRCA1 protein. This residue sits in the region between the coiled-coil domain and the BRCT repeats²² BRCT repeats
BRCA1 C-terminal domains that recognize phosphorylated proteins at DNA damage sites; critical for recruiting repair factors to double-strand breaks. The change replaces a large, negatively charged amino acid (glutamic acid) with the smallest amino acid (glycine), potentially altering local protein flexibility and interactions.

Functional studies³³ Functional studies
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 comparing allele frequencies of E1038G between cancer cases and controls showed no statistically significant difference, consistent with benign status. Large-scale variant classification analyses⁴⁴ variant classification analyses
Easton DF et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet, 2007 applying multifactorial likelihood methods confirmed that E1038G retains near-normal BRCA1 function and is classified as benign or likely benign — it does not break the protein.

The question is whether this common polymorphism subtly modifies BRCA1 efficiency under conditions of DNA damage stress, enough to shift population-level cancer risk by a small margin without being individually pathogenic.

The Evidence

GWAS and association studies. Large-scale genome-wide association studies have mapped the 17q21 region containing BRCA1 as harboring common breast cancer susceptibility variants. A landmark GWAS⁵⁵ landmark GWAS
Easton DF et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007 established the framework for understanding how common variants in cancer-associated gene regions contribute to polygenic risk, with individual effect sizes typically in the OR 1.05-1.30 range — far below the 5-10x risk seen with pathogenic mutations.

A large-scale GWAS meta-analysis⁶⁶ large-scale GWAS meta-analysis
Michailidou K et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet, 2015 of more than 120,000 individuals identified 15 new breast cancer susceptibility loci, establishing that breast cancer risk has a significant polygenic component involving many common variants of small individual effect.

Risk modification context. The EMBRACE prospective analysis⁷⁷ EMBRACE prospective analysis
Mavaddat N et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst, 2013 followed BRCA1 and BRCA2 mutation carriers prospectively and estimated cumulative cancer risks, providing the quantitative risk context for understanding how common variants like E1038G differ from pathogenic BRCA1 mutations in their magnitude of effect. This underscores that common variants like E1038G are far removed from the penetrance of true BRCA1 mutations.

ClinVar consensus. The majority of ClinVar submissions classify E1038G as benign or likely benign (ClinVar variation ID 55398). The variant's high population frequency (~33% in Europeans) itself argues against pathogenicity — a truly harmful BRCA1 variant could not persist at this frequency. Some submitters note it as a variant of uncertain significance, reflecting the ambiguity of its small epidemiological signals.

Practical Implications

The key message: this variant does not warrant the clinical actions associated with pathogenic BRCA1 mutations. Prophylactic mastectomy, risk-reducing salpingo-oophorectomy, and intensive MRI surveillance protocols are for confirmed pathogenic BRCA1/2 carriers — not for carriers of this common polymorphism.

For women carrying one or two copies of the C allele, the evidence supports awareness rather than alarm. If you have additional breast cancer risk factors (family history, other genetic variants, dense breast tissue), this variant may be one small piece of a larger polygenic picture. In that context, discussing supplemental screening with your provider is reasonable.

For everyone, maintaining robust DNA repair capacity through adequate micronutrient intake is sensible. Folate, zinc, and selenium all play roles in DNA repair and genomic stability — though these are most relevant for carriers who want to optimize the DNA repair pathways this gene supports.

Interactions

The E1038G variant exists in a broader context of BRCA1 region variation. The related variant rs1799950 (BRCA1 E1038G's neighboring polymorphism) and rs11571833 (BRCA2 K3326X, a moderate-penetrance truncating variant) may combine with E1038G in polygenic risk models. Studies of polygenic risk scores for breast cancer incorporate many such common variants, and the combined effect of multiple small-effect alleles can meaningfully stratify risk across the population — even when each individual variant contributes only modestly.

The rare variant rs555607708 (BRCA1 pathogenic) represents the opposite end of the spectrum: a high-penetrance mutation that abolishes BRCA1 function. If a user carries both a common E1038G allele and a rare pathogenic BRCA1 variant on the other allele, the clinical management is driven entirely by the pathogenic mutation, not the common polymorphism.

CD58, also known as LFA-3 (Lymphocyte Function-Associated Antigen 3)¹¹ LFA-3 (Lymphocyte Function-Associated Antigen 3)
LFA-3 is a cell-surface glycoprotein expressed on antigen-presenting cells, endothelium, and non-immune cells; it binds CD2 on T cells to stabilise the immune synapse and transmit co-stimulatory signals, is a pivotal regulator of T-cell activation and immune tolerance. rs1016140 sits within the CD58 gene's intronic region (chromosome 1, position 116533925 on GRCh38) and has been independently associated with susceptibility to neuromyelitis optica (NMO) and autoimmune thyroid disease through distinct mechanisms — making it a noteworthy second signal at the CD58 locus beyond the well-characterised rs2300747.

Unlike rs2300747, where the G allele is protective by raising CD58 expression and boosting regulatory T-cell (Treg) function, rs1016140 exhibits a more complex allelic landscape: the G allele increases T-cell activity (raising NMO susceptibility), while the homozygous TT genotype reduces CD58 surface expression on antigen-presenting cells (raising autoimmune thyroid disease susceptibility). Both mechanisms converge on dysregulation of T-cell tolerance, but through opposite directions of CD58 function.

The Mechanism

G allele and NMO: In silico analysis of the four CD58 intronic SNPs associated with NMO found no evidence of alternative splicing or exonic splicing effects. However, the Korean study by Kim et al. proposed that the rs1016140 G allele enhances T-cell co-stimulatory activity²² rs1016140 G allele enhances T-cell co-stimulatory activity
CD2–LFA-3 signalling amplifies T-cell receptor responses; when these signals are heightened, inflammatory T cells may more readily breach the blood–brain barrier, creating the neuroinflammatory milieu required for AQP4 antibodies to access the central nervous system and damage astrocytes. In NMO, unlike MS, the primary injury is antibody-mediated destruction of aquaporin-4 (AQP4)³³ aquaporin-4 (AQP4)
AQP4 is the most abundant water channel in the CNS, expressed on astrocyte endfeet; NMO-IgG autoantibodies bind AQP4 and trigger complement-mediated astrocyte destruction on astrocytes — but T-cell-driven inflammation is required to open the blood–brain barrier and allow these antibodies to reach their target.

TT genotype and autoimmune thyroid disease: Zhao et al. (2020) found that the TT genotype at rs1016140 is significantly more common in both Graves' disease and Hashimoto's thyroiditis patients than in healthy controls, and is associated with reduced CD58 (LFA-3) surface expression on monocytes. Lower LFA-3 levels weaken the CD2–CD58 co-stimulatory signal in regulatory T cells⁴⁴ CD2–CD58 co-stimulatory signal in regulatory T cells
FoxP3+ regulatory T cells require CD2-mediated signalling to maintain their suppressive phenotype; reduced LFA-3 availability impairs Treg induction and peripheral tolerance, analogous to the mechanism proposed for the rs2300747 A allele in MS — both converge on deficient Treg activity, but via different allelic directions at different positions in the CD58 intron.

The Evidence

The primary NMO association was established by Kim et al. 2014 in BMC Neurology⁵⁵ Kim et al. 2014 in BMC Neurology
98 NMO patients and 237 controls from a Korean population; genotyping of six CD58 SNPs. rs1016140 showed a significant allelic association with NMO (OR 1.76, 95% CI 1.25–2.47, P = 0.005; corrected P = 0.02): the G allele was present in 53.5% of NMO patients compared to 39.5% of controls. rs1016140 was also a constituent of the NMO-associated haplotypes CD58_ht1 and CD58_ht3, both of which reached statistical significance after multiple-testing correction.

Replication across populations has been partial but consistent. A Han Chinese study (Guo et al. 2017, Journal of Neuroimmunology) confirmed rs1016140 among five CD58 SNPs significantly associated with NMOSD risk, alongside rs2300747, rs1335532, rs56302466, and rs12044852. The converging evidence from two independent East Asian populations strengthens the case for a real, if modest, independent contribution of rs1016140 to NMO susceptibility.

For autoimmune thyroid disease, Zhao et al. 2020⁶⁶ Zhao et al. 2020
177 Graves' disease patients, 193 Hashimoto's thyroiditis patients, 116 healthy controls; PCR-RFLP genotyping demonstrated that the TT genotype at rs1016140 (SNP4 in their notation) was significantly enriched in both autoimmune thyroid disease patient groups relative to controls, and functionally confirmed that these CD58 risk genotypes correlate with lower CD58 surface expression on monocytes.

The overall evidence level is rated moderate: the NMO signal has been replicated in two East Asian populations but not yet in European cohorts, sample sizes are modest (the Korean study included only 98 NMO cases), and the molecular mechanism of rs1016140 specifically has not been resolved at the same level of detail as rs2300747.

Practical Actions

For individuals carrying the GG genotype (two G alleles), awareness of NMO as a distinct demyelinating condition is clinically relevant. NMO differs from MS in its reliance on AQP4-IgG and in preferring the spinal cord and optic nerves as primary targets; misdiagnosis as MS can lead to suboptimal treatment. Vitamin D optimisation supports Treg function through parallel FoxP3-related pathways and is the principal modifiable lever available.

For TT carriers, the finding that reduced CD58 expression suppresses regulatory T cells points to the same Treg-support strategy relevant throughout the CD58 locus: vitamin D sufficiency is the best-characterised modifiable intervention.

There is no supplement or medication that directly compensates for altered CD58 expression at this locus. Interventions are therefore primarily monitoring- and awareness-focused.

Interactions

rs1016140 is located within the same CD58 intronic locus as rs2300747 (the well-characterised MS signal). The two variants are not in complete linkage disequilibrium — the NMO study showed rs1016140 providing a distinct association signal, and the AITD study focused on rs1016140 independently. The degree of LD between rs1016140 and rs2300747 in different ancestry groups has not been fully characterised, but the divergent risk-allele directions (G = risk at rs1016140 for NMO; G = protective at rs2300747 for MS) strongly implies they are not simply tagging the same functional variant.

The CD58 locus also converges with rs6897932 (IL7R)⁷⁷ rs6897932 (IL7R)
IL7R regulates T-cell homeostasis and regulatory T-cell survival, a pathway overlapping with CD58-mediated Treg co-stimulation and rs2476601 (PTPN22)⁸⁸ rs2476601 (PTPN22)
PTPN22 modulates TCR-proximal activation thresholds; together with CD58, it contributes to the cumulative genetic burden on T-cell tolerance. Individuals carrying high-risk alleles at multiple T-cell regulatory loci face compounding effects on immune tolerance.